trending Market Intelligence /marketintelligence/en/news-insights/trending/X6I9kd6bqWMNfmdVRimu2w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Drug development services provider PPD files for $100M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption

Street Talk Podcast

Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4

Street Talk Podcast

Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief

Drug development services provider PPD files for $100M IPO

PPD Inc., a Wilmington, N.C.-based provider of drug development services, filed for an IPO of its common stock to raise up to $100 million.

The contract research organization — led by chairman and CEO David Simmons — plans to list its shares on the Nasdaq Global Select Market under the ticker symbol PPD.

Hellman & Friedman LLCPPD, formerly known as Eagle Holding Co. I, was formed as a corporation in Delaware on April 13, 2017. It is a holding company with no material direct operations, and its principal assets are the Eagle Holding Co. II common shares that it holds.

Eagle Holding Co. II is the indirect parent of Pharmaceutical Product Development LLC, which, together with its subsidiaries, owns substantially all of PPD operating assets.

Private equity investment firms Hellman & Friedman LLC and Carlyle Group LP are among the sponsors of PPD with 56.7% and 23.8% stakes, respectively.

PPD plans to use net proceeds from the offering coupled with cash on hand to redeem $550 million of notes issued by Eagle Holding Co. II in May 2017 and to redeem $900 million of notes issued by Eagle Holding Co. II in May 2019.

Barclays, J.P. Morgan Securities LLC., Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, BofA Securities LLC, Credit Suisse Securities LLC, Jefferies LLC, UBS Securities LLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Evercore Group LLC, HSBC Securities Inc., Mizuho Securities, Robert W. Baird & Co. Inc. and William Blair & Co. LLC are the underwriters on the IPO.